Research-informed screening strategy

Multi-Target Virtual Screening Services: Optimize the Target Profile, Not One Score

Some programs need activity across several disease targets; others need potency on one target and avoidance of close homologs, resistance mutants, or safety anti-targets. We build a matched screening framework that turns cross-target evidence into an interpretable compound-by-target profile.

Discuss your project Choose a screening route

Multi-target virtual screening across disease targets and anti-targets

Problems this service solves

Turn an Uncertain Search into a Defined Decision

Every project is scoped around the scientific uncertainty, the available evidence, and the number of candidates your team can validate.

A disease mechanism requires coordinated multi-target activity

Prioritize compounds with a balanced predicted profile instead of the best score against only one target.

Selectivity within a protein family is critical

Compare homologs and anti-targets under matched preparation and scoring conditions.

Resistance mutations threaten a lead series

Identify compounds whose binding hypothesis is less dependent on mutation-sensitive contacts.

Start from the target profile your program needs

Can We Support Your Multi-Target Screening Project?

Define desired activities, targets to avoid, and acceptable tradeoffs before candidates are compared across a matched target panel.

Your Starting Point	You Provide	We Build	You Receive
A disease mechanism requires activity across several targets	Required and optional targets Desired balance or weighting Structures, models, or known ligands Compound library and assay capacity	Target-panel readiness assessment Matched preparation and screening Per-target evidence and uncertainty review Balanced-profile or Pareto prioritization	Compound-by-target profile matrix Balanced polypharmacology candidates Per-target poses and interactions Multi-assay validation plan
A lead must distinguish close homologs or family members	Primary target and homolog panel Required selectivity window Lead series or candidate library Known selectivity or assay data	Binding-site comparison Matched cross-target protocols Differential interaction analysis Selectivity-aware ranking and clustering	Predicted selectivity profiles Residue-level differentiation hypotheses Risk and confidence flags Counter-screen priorities
Wild-type and resistance variants must remain covered	Wild-type and mutant structures or sequences Resistance mutations of interest Known compounds and activity shifts Desired coverage rule	WT–mutant structural harmonization Matched pose and interaction analysis Mutation-sensitive contact mapping Coverage and robustness ranking	WT–mutant candidate matrix Mutation-resilient binding hypotheses Vulnerability flags Resistance-focused test set
Safety or mechanism anti-targets must be avoided	Desired target and anti-target list Known safety liabilities Exposure or tissue context Lead series or screening library	Anti-target panel preparation Cross-target screening and evidence review Liability and uncertainty flagging Profile-based candidate selection	Desired-versus-undesired profile matrix Lower-risk candidate tiers Potential off-target binding modes Safety counter-screen plan

Minimum starting point: a defined target panel and an explicit desired profile. Raw scores from different proteins are not treated as directly comparable without calibration and uncertainty review.

Illustrative result package

See What a Multi-Target Screening Project Delivers

The result makes target-by-target evidence visible so a seemingly strong composite score cannot hide a critical selectivity, resistance, or safety tradeoff.

Target Product Profile Matched Target Panel Per-Target Screening Profile Comparison Balanced Test Set

Explain the Candidate Profile

Each compound is reviewed against the profile agreed before screening.

Desired engagement: evidence for primary and secondary disease-relevant targets.
Required avoidance: potential activity against homologs, anti-targets, or liability targets.
Structural rationale: target-specific poses, conserved contacts, and differentiating residues.
Tradeoffs: uncertainty, missing structures, score comparability, and profile compromises.

Choose Balanced Candidates Transparently

We preserve target-level evidence instead of collapsing every result into one opaque score.

Profile matrix with confidence and coverage flags
Pareto or rule-based candidate tiers
Chemically diverse primary compounds and backups
Matched on-target and counter-screen recommendations

Example Compound-by-Target Decision Matrix

Qualitative tiers are shown because raw docking scores from different proteins should not be interpreted as universally comparable.

Illustrative data

Priority	Compound	Primary Target	Secondary Target	Resistance Variant	Anti-Target	Profile Fit	Decision
01	MT-104	Strong	Moderate	Strong	Low	Best balanced	Advance
02	MT-218	Strong	Strong	Moderate	Low	Polypharmacology fit	Advance
03	MT-327	Moderate	Strong	Strong	Low	Diverse backup	Advance
04	MT-451	Strong	Low	Strong	Low	Secondary gap	Review
05	MT-566	Strong	Moderate	Low	Low	Mutation risk	Review
06	MT-642	Strong	Strong	Strong	Moderate	Anti-target risk	Hold
07	MT-735	Moderate	Low	Low	Low	Insufficient coverage	Hold

Interpretation note: a cross-target profile is a prioritization hypothesis. Confidence depends on target structure quality, protocol comparability, calibration evidence, and experimental confirmation across the relevant target panel.

Research applications

Where This Screening Strategy Creates Value

The method is selected for the scientific decision—not used as a one-size-fits-all calculation.

Polypharmacology

Search for compounds expected to engage a defined set of disease-relevant targets.

Family Selectivity

Prioritize chemical matter that distinguishes kinases, proteases, GPCRs, or related enzymes.

WT–Mutant Coverage

Compare binding hypotheses across wild-type and resistance-associated variants.

Safety Anti-Target Filtering

Deprioritize candidates with plausible binding to selected liability targets.

Combination Strategy

Map separate compounds across a target network to support rational combination hypotheses.

Network Pharmacology

Connect screening profiles with pathways and disease modules for mechanism-focused prioritization.

Decision-gated workflow

From Project Question to Experiment-Ready Shortlist

Define the target product profile

Specify required, optional, and prohibited activities and how tradeoffs should be handled.
Harmonize the target panel

Select comparable structures and binding sites and document differences that affect interpretation.
Run matched screens

Apply consistent preparation, sampling, and evidence collection across all targets.
Normalize and compare

Separate within-target ranking from cross-target interpretation and flag uncertainty or non-comparable cases.
Build the profile matrix

Summarize desired interactions, potential liabilities, and profile tradeoffs for each candidate.
Nominate balanced candidates

Select compounds that best satisfy the defined profile and design the experimental panel needed to verify it.

Quality gates

Three Checks Before a Candidate Is Recommended

Gate 01

Input Fitness

Are the structure, ligand data, target panel, and library suitable for the chosen method?

Gate 02

Evidence Convergence

Do orthogonal scores, interactions, chemistry, and biological context support the same candidates?

Gate 03

Experimental Actionability

Can the shortlist be sourced, tested, interpreted, and used to make the next program decision?

Defined outputs

Deliverables Built for the Next Experimental Decision

Files, evidence, and recommendations are organized so your team can review the selection logic and move candidates into testing.

Target Panel

Coverage map
Structure notes
Site comparability

Profile Matrix

Per-target scores
Confidence flags
Desired/undesired profile

Structural Evidence

Target-specific poses
Interaction differences
Mutation context

Testing Strategy

Balanced shortlist
Counter-screens
Decision criteria

Related screening methods

Choose the Evidence Route That Matches Your Project

Methods can be used alone or combined as a consensus workflow when the inputs and decision justify it.

FAQs

Frequently Asked Questions

Not reliably without careful calibration. We preserve within-target rankings, apply normalization where justified, and add confidence flags rather than treating raw scores as universally comparable.

An anti-target is a protein for which predicted or measured engagement is undesirable because of safety, selectivity, or mechanism concerns.

Yes. Wild-type and mutant structures can be screened as a matched panel to prioritize compounds with more consistent binding hypotheses across variants.

The desired target profile and weights are agreed before screening. Pareto-style analysis can identify candidates that provide the best available balance without hiding compromises in a single composite score.